Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) Return on Equity (2023 - 2025)

Immunome's Return on Equity history spans 3 years, with the latest figure at 0.5% for Q4 2025.

  • For Q4 2025, Return on Equity rose 105.0% year-over-year to 0.5%; the TTM value through Dec 2025 reached 0.5%, up 105.0%, while the annual FY2025 figure was 0.55%, 148.0% up from the prior year.
  • Return on Equity reached 0.5% in Q4 2025 per IMNM's latest filing, up from 0.88% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.5% in Q4 2025 to a low of 1.74% in Q4 2023.
  • Average Return on Equity over 3 years is 1.1%, with a median of 1.01% recorded in 2024.
  • Peak YoY movement for Return on Equity: rose 19bps in 2024, then surged 105bps in 2025.
  • A 3-year view of Return on Equity shows it stood at 1.74% in 2023, then increased by 11bps to 1.54% in 2024, then soared by 68bps to 0.5% in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Return on Equity are 0.5% (Q4 2025), 0.88% (Q3 2025), and 0.78% (Q2 2025).